Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza A virus H5N1 vaccines - Ology Bioservices

Drug Profile

Influenza A virus H5N1 vaccines - Ology Bioservices

Alternative Names: A/H5N1 pre-pandemic influenza vaccine (whole virion, vero cell derived, inactivated); Cell culture-based pandemic avian influenza (bird flu) vaccine - Shire; Cell cultured influenza H5N1 vaccine prototype; Cell cultured influenza pre-pandemic H5N1 vaccine; Celvapan H5N1 vaccine - Shire; H5N1 reverse genetic reassorted (RG) Indonesia strain (clade 2) vaccine - Shire/US Department of Health and Human Services; H5N1 Vietnam strain (clade 1) vaccine - Shire/NIAID; Pandemic influenza clade 2 strain vaccine candidate - Shire; Pandemic influenza vaccine H5N1 Shire; Vepacel; Whole virion, vero cell-derived influenza vaccine containing H5N1 HA antigen - Baxter Healthcare Corporation

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baxter International
  • Developer Baxter International; National Institute of Allergy and Infectious Diseases
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Influenza A virus H5N1 subtype
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza A virus H5N1 subtype

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(Prevention) in USA (IM, Injection)
  • 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top